Key result
Two human induced pluripotent stem cell lines (HIMRi002-A and HIMRi003-A) were successfully generated from dermal fibroblasts of patients with Caveolinopathy carrying the p.A46T CAV3 mutation.
The generated hiPSC lines provide a validated in vitro model for studying CAV3-associated pathomechanisms and developing new therapeutic options for caveolinopathies.
Answers are grounded in this paper and cite their sources.
These hiPSC lines enable CAV3 cardiomyopathy modeling; leaves open clinical translation pending functional validation.
Here we introduce the human induced pluripotent stem cell lines (hiPSCs), HIMRi002-A and HIMRi003-A, generated from cultured dermal fibroblasts of 61-year-old (HIMRi002-A) and 38-year-old (HIMRi003-A) female patients, carrying a known heterozygous pathogenic variant (p.A46T) in the Caveolin 3 (CAV3) gene, via lentiviral expression of OCT4, SOX2, KLF4 and c-MYC. HIMRi002-A and HIMRi003-A display typical embryonic stem cell-like morphology, carry the p.A46T CAV3 gene mutation, express several pluripotent stem cell markers, retain normal karyotype (46, XX) and can differentiate in all three germ layers. We postulate that the HIMRi002-A and HIMRi003-A iPSC lines can be used for the characterization of CAV3-associated pathomechanisms and for developing new therapeutic options.
No takes yet. Share an insight, caveat, or question.
Boeing et al. (2023) studied Caveolinopathy, rippling muscle disease (n=2). Lentiviral expression of OCT4, SOX2, KLF4 and c-MYC was evaluated on Generation and characterization of hiPSC lines. Two human induced pluripotent stem cell lines (HIMRi002-A and HIMRi003-A) were successfully generated from dermal fibroblasts of patients with Caveolinopathy carrying the p.A46T CAV3 mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: